Insmed Incorporated (BIT:1INSM)
Italy · Delayed Price · Currency is EUR | Market Cap | 21.26B -37.3% |
| Revenue (ttm) | 1.34B +240.0% |
| Net Income | -533.30M |
| EPS | -2.52 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 96.98 |
| Previous Close | 98.50 |
| Day's Range | 96.98 - 96.98 |
| 52-Week Range | 79.25 - 180.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 29, 2026 |
About Insmed
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 ... [Read more]
Financial Performance
In 2025, Insmed's revenue was $606.42 million, an increase of 66.73% compared to the previous year's $363.71 million. Losses were -$1.28 billion, 39.7% more than in 2024.
Financial numbers in USD Financial StatementsNews
Insmed to Present at November and December 2026 Investor Conferences
BRIDGEWATER, N.J., Nov. 4, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform ...
Insmed assumed with a Buy at H.C. Wainwright
H.C. Wainwright analyst Matthew Caufield assumed coverage of Insmed (INSM) with a Buy rating and $220 price target The firm says Brinsupri is the first and only FDA-approved therapy for…
Insmed price target raised to $158 from $154 at Mizuho
Mizuho raised the firm’s price target on Insmed (INSM) to $158 from $154 and keeps an Outperform rating on the shares.
Insmed price target lowered to $201 from $205 at Guggenheim
Guggenheim lowered the firm’s price target on Insmed (INSM) to $201 from $205 and keeps a Buy rating on the shares.
Insmed price target raised to $204 from $198 at Roth Capital
Roth Capital raised the firm’s price target on Insmed (INSM) to $204 from $198 and keeps a Buy rating on the shares, noting that Brinsupri sales of $400.1M in Q3…
Insmed Earnings Call Transcript: Q3 2026
Q3 revenue growth lifted FY 2026 guidance for both commercial products, while liquidity and the BRINSUPRI trajectory support expected cash flow positivity in 2027. Pipeline trials and potential label expansions remain major growth catalysts.
Insmed Quarterly report: Q3 2026
Insmed has published its Q3 2026 quarterly earnings report on October 29, 2026.
Insmed Earnings release: Q3 2026
Insmed released its Q3 2026 earnings on October 29, 2026, summarizing the period's financial results.
Insmed Slides: Q3 2026
Insmed has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 29, 2026.
Insmed reports Q3 EPS (46c), consensus (38c)
Reports Q3 revenue $524.4 M, consensus $499.48M. “Q3 marked another period of meaningful progress, defined by commercial momentum, regulatory achievements, and advancement across our diversified pipel...
Insmed updates 2026 outlook
The Company raised 2026 revenue guidance for BRINSUPRI to $1.35B-$1.4B from $1.25B-$1.4B. Raised 2026 revenue view for ARIKAYCE to $460M-$470M from $450M-$470M. Continues to anticipate peak revenues f...
Insmed price target lowered to $154 from $195 at Mizuho
Mizuho lowered the firm’s price target on Insmed (INSM) to $154 from $195 and keeps an Outperform rating on the shares.
Insmed Reports Third-Quarter 2026 Financial Results and Provides Business Update
—Total Company Revenues of $524.4 Million for the Third Quarter of 2026— —BRINSUPRI ® (brensocatib) Revenues of $400.1 Million for the Third Quarter of 2026, Reflecting 29% Growth Over the Second Qua...
Insmed Slides: Investor presentation
Insmed has posted slides in relation to its latest quarterly earnings report, which was published on October 28, 2026.
Insmed price target lowered to $213 from $218 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Insmed (INSM) to $213 from $218 and keeps an Overweight rating on the shares.
Insmed price target lowered to $173 from $187 at Raymond James
Raymond James lowered the firm’s price target on Insmed (INSM) to $173 from $187 and keeps an Outperform rating on the shares. A stock-moving quarter requires revenue above expectations, durable…
Insmed Appoints Two New Directors to Its Board
—Paul Hudson, Former CEO of Sanofi and Novartis Pharmaceuticals, and Utpal Koppikar, CFO of Verily Health and Veteran Biopharma Finance Leader, Join as New Independent Directors— BRIDGEWATER, N.J., Oc...
Insmed announces commercial launch of brinsupri tablets in Japan
Insmed (INSM) announced the commercial launch in Japan of brinsupri tablets 25 mg, an oral, once-daily treatment for non-cystic fibrosis bronchiectasis in adults and pediatric patients 12 years and ol...
Insmed Launches BRINSUPRI® Tablets 25 mg (brensocatib hydrate) for the Treatment of Non-Cystic Fibrosis Bronchiectasis in Japan
—BRINSUPRI, a First-in-Disease and First-in-Class Treatment for Patients With Non-Cystic Fibrosis Bronchiectasis (NCFB), Is Now Available by Prescription in Japan— BRIDGEWATER, N.J., Oct. 19, 2026 /PR...
Insmed Features the Global Phase 3 PALM Clinical Development Program Evaluating Treprostinil Palmitil Inhalation Powder (TPIP) at CHEST 2026
—Insmed's Largest Parallel-Running Clinical Effort to Date With Four Pivotal Phase 3 Studies Advancing Across Four Progressive Pulmonary Diseases: PALM-PAH, PALM-ILD, PALM-PPF, and PALM-IPF— —One of t...
Insmed to Present New Data Across Its Respiratory Portfolio at CHEST 2026 and IDWeek 2026
—Three Late-Breaking Abstracts at CHEST 2026 Deepen Understanding of the Potential of Treprostinil Palmitil Inhalation Powder (TPIP) Across Pulmonary Arterial Hypertension (PAH) and Pulmonary Hyperten...
Insmed price target lowered to $207 from $214 at BofA
BofA analyst Jason Zemansky lowered the firm’s price target on Insmed (INSM) to $207 from $214 and keeps a Buy rating on the shares after updating estimates ahead of the…
Insmed downgraded to Peer Perform from Outperform at Wolfe Research
Wolfe Research downgraded Insmed (INSM) to Peer Perform from Outperform without a price target The firm says finding a pool of comorbid patients for Brinsupri may be stretched beyond mid…
Insmed announces CFO Sara Bonstein to step down
Insmed (INSM) announced that Sara Bonstein will step down as CFO. Bonstein will continue to serve as CFO until October 30, 2026, to ensure a smooth transition through the company’s…
Insmed backs FY26 brinsupri revenue view $1.25B-$1.4B
As Insmed (INSM) continues to build on its operational excellence and momentum, the company reaffirms its full-year 2026 financial guidance of revenue in the range of $1.25B-$1.4B for brinsupri and…